Athira Pharma stock loses two-thirds of its value after study of Alzheimer’s treatment misses primary endpoint


Shares of Athira Pharma Inc. apha plummeted 66.9% toward a record low in active afternoon trading Wednesday, enough to make them the biggest decliners trading on major market indexes, after the biopharmaceutical company said a Phase 2 study of its Alzheimer’s treatment failed to meet the primary endpoint. Trading volume spiked up to 18.1 million shares, compared with the full-day average over the past 30 days of about 246,500 shares. The company said the primary endpoint of a change in biomarker event-related-potential (ERP) P300 latency “was not statistically significant” for the full study population. However, Athira said a pre-specified subgroup analysis indicated a potential diminished effect of fosgonimeton when given in combination with standard-of-care AchEls. Fosgonimeton is designed to help promote brain health and function. The stock, which was headed for the biggest one-day selloff since it went public in September 2020, has plunged 78.5% year to date, while the iShares Biotechnology ETF IBB, +1.23% has slid 25.2% and the S&P 500 SPX, -0.13% has dropped 20.5%.

This article was originally published by Read the original article here.

Previous articleTax Guy: I need cash. How bad is it to take money out of my IRA?
Next articleNasdaq Composite overcomes early decline to post modest gain


Please enter your comment!
Please enter your name here